OmniAb heads into its third-quarter report with an unusual setup: the stock has more than doubled since the last report, yet the quarter itself is expected to look far weaker than the one before it. That is not a sign of trouble so much as a feature of the business model. OmniAb licenses its antibody discovery platforms to drug developers and collects milestone payments as partner programs advance. Management has said 2026 milestone revenue is heavily front-loaded, so after a $13.4 million second quarter, the Street is bracing for a return to lumpy, low-single-digit millions.

Consensus calls for revenue of about $3.6 million and a loss of $0.12 per share. That revenue figure would still be up roughly 62% from the $2.2 million posted a year ago, and the loss would be modestly narrower than last year's $0.14. But it would be a much wider loss than the $0.05 reported last quarter, because operating costs are fairly fixed. Management tightened its cash operating expense outlook to $51 million to $55 million, meaning roughly $13 million of spending each quarter with or without a big milestone to absorb it.

Guidance frames the bar. OmniAb has raised its full-year revenue outlook three times, from $25 million to $30 million initially, to $28 million to $33 million, and most recently to $32 million to $36 million. With $27.8 million booked in the first half, the range implies only about $4 million to $8 million across the second half, so a $3.6 million third quarter fits comfortably inside the plan. The full-year consensus of about $31.1 million actually sits below the bottom of management's range, which suggests some estimates have not caught up or that analysts doubt the late-year milestones will land on time. A result near or above consensus, paired with a reaffirmed or higher range, would close that gap in OmniAb's favor.

The more important evidence will come from the pipeline rather than the income statement. Last quarter's standout development was two partner programs jumping straight from Phase 1 to Phase 3, Johnson & Johnson's multiple myeloma tri-specific and Merck KGaA's colorectal cancer antibody-drug conjugate. These are the programs that could eventually generate royalties, though partner launches are not expected until around 2028. Investors should look for continued growth in active partners, which reached 110, and active programs, which hit 425, along with progress on the 34 clinical-stage programs and approved products. Signs that the Argenx and Enrosa licenses are producing early work, that Teva's anti-IL-15 program remains on track for a Phase 2b vitiligo start in the fourth quarter, and that the Exploration platform can build on its first two instrument sales would all validate the narrative. A further decline in remaining contracted clinical milestones, which slipped to about $340 million from $350 million, or a cut to the year-end cash target of $37 million to $41 million, would challenge it. The report is also the first quarterly checkpoint since the investor and analyst day management scheduled for early October, so any longer-term targets laid out there will now face their first test.

Sentiment has soured even as the shares soared. Bearish readings have deepened to roughly 47% from about 21% before the last report, a sign that many expect the quieter quarter to deflate enthusiasm. The stock, at $4.92, trades nearly double its 200-day moving average and well above last quarter's $1.52 to $2.79 range, though it sits about 9% below its post-earnings high of $5.43, so it is not pressing a breakout.

Ultimately, the headline numbers matter less than whether OmniAb can show that its milestone-driven surge reflects a deepening, maturing pipeline rather than a one-time windfall. Steady partner and program growth, intact guidance and a reaffirmed cash outlook would keep the story on track despite a softer quarter.